Aryl Sulfotransferase IV Deficiency in Rat Liver Carcinogenesis Initiated with Diethylnitrosamine and Promoted withN-2-Fluorenylacetamide or Its C-9-Oxidized Metabolites-Reference-Cited by-同舟云学术

Aryl Sulfotransferase IV Deficiency in Rat Liver Carcinogenesis Initiated with Diethylnitrosamine and Promoted withN-2-Fluorenylacetamide or Its C-9-Oxidized Metabolites

Published:1997-04 Issue:2 Volume:64 Page:63-77
ISSN:0014-4800
Container-title:Experimental and Molecular Pathology
language:en
Short-container-title:Experimental and Molecular Pathology

Author:

Malejka-Giganti D.,Ringer D.P.,Vijayaraghavan P.,Kiehlbauch C.C.,Kong J.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Molecular Biology,Pathology and Forensic Medicine

Reference43 articles.

1. Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons;Beland,1990

2. DNA adducts and carcinogenesis;Beland,1989

3. Sulfations ofN;Blanck;Toxicol. Pathol.,1987

4. Purification and immunochemical characterization of a male-specific rat liver oestrogen sulphotransferase;Borthwick;Biochem. J.,1993

5. Enzyme- and sex-specific differences in the intralobular localizations and distributions of aryl sulfotransferase IV (tyrosine-ester sulfotransferase) and alcohol (hydroxysteroid) sulfotransferase a in rat liver;Chen;Drug Metab. Dispos.,1995

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutagenicity of aromatic amines and amides with chemical models for cytochrome P450 in Ames assay;Toxicology in Vitro;2009-09

2. Oxidative transformation of 2-acetylaminofluorene by a chemical model for cytochrome P450: A water-insoluble porphyrin and tert-butyl hydroperoxide;Bioorganic & Medicinal Chemistry;2008-07

3. Activation Mechanism of 2-Acetylamino-9-fluorenone as a Mutagen in Salmonella typhimurium;Genes and Environment;2008

4. Syntheses of 3-Ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels;Bioorganic & Medicinal Chemistry;2003-08

5. Cancer and Phase II Drug-Metabolizing Enzymes;Current Drug Metabolism;2003-02-01